asked the Secretary of State for Social Services whether the advisory committee on borderline substances has reconsidered the evidence on Nicorette; and what recommendations it has made.
At its last meeting, the advisory committee on borderline substances reviewed the available evidence on the use of Nicorette, including the as yet unpublished results of a large recent trial. In its view, the case that this product was of therapeutic value when used in the normal circumstances of general practice remained unproven. Accordingly, it was unable to recommend that Nicorette should be regarded as a drug when prescribed by general medical practitioners. It will keep the position under review, and will give careful consideration to any further evidence which becomes available.